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Reduced lung function predicts mortality and is key to the diagnosis of COPD. In a genome-wide
association study in 400,102 individuals of European ancestry, we define 279 lung function signals,
139 of which are new. In combination, these variants strongly predict COPD in independent patient
populations. Furthermore, the combined effect of these variants showed generalisability across
smokers and never-smokers, and across ancestral groups. We highlight biological pathways, known
and potential drug targets for COPD and, in phenome-wide association studies, autoimmune-related
and other pleiotropic effects of lung function associated variants. This new genetic evidence has
potential to improve future preventive and therapeutic strategies for COPD.
Introduction
Impaired lung function is predictive of mortality1 and is the key diagnostic criterion for chronic
obstructive pulmonary disease (COPD). Globally, COPD accounted for 2.9 million deaths in 20162,
being one of the key causes of both Years of Life Lost and Years Lived with Disability worldwide3.
Determinants of maximally attained lung function and of lung function decline can influence the risk
of developing COPD. Tobacco smoking is the single largest risk factor for COPD, although other
environmental exposures and genetic makeup are important4,5. Genetic variants associated with
lung function and COPD susceptibility can provide aetiological insights, assisting with risk prediction,
as well as drug target identification and validation6. Whilst there has been considerable progress in
identifying genetic markers associated with lung function and risk of COPD4,7-19 seeking a high yield
of associated genetic variants is key to progressing knowledge because: (i) implication of multiple
molecules in each pathway will be needed to build an accurate picture of the pathways
underpinning development of COPD; (ii) not all proteins identified will be druggable and; (iii)
combining information across multiple variants can improve prediction of disease susceptibility.
Through new detailed quality control and analyses of spirometric measures of lung function in UK
Biobank and expansion of the SpiroMeta Consortium, we undertook the largest genome-wide
association study of lung function performed to date. Our study entailed a near seven-fold increase
in sample size over previous studies of similar ancestry to address the following aims: (i) to generate
a high yield of genetic markers associated with lung function; (ii) to confirm and fine-map previously
reported lung function signals; (iii) to investigate the putative causal genes and biological pathways
through which lung function associated variants act, and their wider pleiotropic effects on other
traits; and (iv) to generate a weighted genetic risk score for lung function and test its association
with COPD susceptibility in individuals of European and other ancestries.
Results
139 new signals for lung function
We increased the sample size available for the study of quantitative measures of lung function in UK
Biobank by refining the quality control of spirometry based on recommendations of the UK Biobank
Outcomes Adjudication Working Group (Supplementary Note). Genome-wide association analyses
of forced expired volume in 1 second (FEV1), forced vital capacity (FVC) and FEV1/FVC were then
undertaken in 321,047 individuals in UK Biobank (Supplementary Table 1) and in 79,055 individuals
from the SpiroMeta Consortium (Supplementary Tables 2 and 3). A linear mixed model approach
implemented in BOLT-LMM20 was used for UK Biobank to account for relatedness and fine-scale
6population structure (Online Methods). A total of 19,871,028 autosomal variants imputed in both
UK Biobank and SpiroMeta were analysed. Peak expiratory flow (PEF) was also analysed genome-
wide in UK Biobank and up to 24,218 samples from SpiroMeta. GWAS results in UK Biobank were
adjusted for the intercept of LD score regression21, but SpiroMeta and the meta-analysis were not as
intercepts were close to 1.00 (Online Methods). All individuals included in the genome-wide
analyses were of European ancestry (Supplementary Figure 1 and Supplementary Note).
To maximise statistical power for discovery of new (previously unreported) signals, whilst
maintaining stringent significance thresholds to minimise reporting of false positives, we adopted a
study design incorporating both two-stage and one-stage approaches (Figure 1). In the two-stage
analysis, 99 new distinct signals, defined using conditional analyses22, were associated with one or
more traits at P<5×10-9 in UK Biobank and showed association (P<10-3) with a consistent direction of
effect in SpiroMeta (“Tier 1” signals, Supplementary Figure 2; Supplementary Table 4). In the one-
stage analysis, we meta-analysed UK Biobank and SpiroMeta (up to 400,102 individuals) and 40
additional new distinct signals associated with one or more lung function traits reaching P<5×10-9
(see 23) were identified (Supplementary Figure 2, Supplementary Table 4) that were also associated
with P<10-3 separately in UK Biobank and in SpiroMeta, with consistent direction of effect (“Tier 2”
signals). An additional 323 autosomal signals were significantly associated with one or more lung
function traits in the meta-analysis of UK Biobank and SpiroMeta (P<5×10-9) and reached P<10-3 for
association in only one of UK Biobank or SpiroMeta (“Tier 3” signals, Supplementary Table 5).
Analysis of association of FEV1, FVC and FEV1/FVC with 240,417 chromosome X variants in 359,226
individuals (321,027 UK Biobank and 38,199 SpiroMeta15) gave an additional 5 Tier 3 signals. Only
the 139 signals meeting Tier 1 and Tier 2 criteria were followed up further. The strength and
direction of association of the sentinel variant (the variant in each signal with the lowest P value) for
these 139 new signals across all 4 lung function traits are shown in Figure 2. Of the 139 signals, 131
were associated with at least two lung function traits at P<10-3, eight signals were unique to
FEV1/FVC and no signals were unique to FEV1, FVC or PEF at this threshold.
We assessed whether any of these 139 signals associated with lung function could be driven via an
underlying association with smoking behaviour (Online Methods). Only rs193686 (in an intron of
MET, Supplementary Table 6) was associated with smoking behaviour. Therefore, we tested for
association between this variant and lung function in never smokers (n=173,658). Whilst rs193686
was associated with smoking initiation (P=9.18×10-6), the allele associated with smoking initiation
was associated with increased lung function in never smokers (FEV1/FVC P=5.28×10-10,
Supplementary Table 7). Therefore, this signal was retained for further analysis.
A total of 279 signals of association for lung function
Of 157 previously published signals of association with lung function and COPD3,6-18, 142 were
associated at P<10-5 in UK Biobank (Online Methods, Supplementary Figure 3, Supplementary Table
8). Two sentinel variants (rs1689510 and rs11134789) were associated with smoking initiation
(Supplementary Table 6), but were also associated with lung function in never smokers
(Supplementary Table 7). SNP rs17486278 at CHRNA5 and rs11667314 near CYP2A6 were each
associated with cigarettes per day (Supplementary Table 6); neither were significantly associated
with lung function among never smokers and so were excluded from further analysis. This brings the
total number of distinct signals of association with lung function to 279 (Supplementary Table 9).
None of these variants showed interaction with ever-smoking status (P>1.8×10-4, Online Methods,
7Supplementary Table 7). Using the effect estimates, allele frequencies and assuming a total
heritability of 40%24,25 (Online Methods), we calculated that the 140 previously reported lung
function signals showing association in this study (UK Biobank P<10-5) explained 5.0%, 3.4%, 9.2%
and 4.5% of the estimated heritability of FEV1, FVC, FEV1/FVC and PEF, respectively. The 139 new
signals reported here, explain an additional 4.3%, 3.3%, 3.9% and 3.3% of the estimated heritability,
respectively.
Identification of putative causal genes
Bayesian refinement was undertaken for each signal to identify the set of variants that were 99%
likely to contain the underlying causal variant (assuming the causal variant has been analysed). The
results from the meta-analysis of UK Biobank and SpiroMeta were used to define the 99% credible
sets (Online Methods, Supplementary Table 10, Supplementary File–Region Plots).
To identify putative causal genes for each signal, we identified deleterious variants and variants
associated with gene expression (eQTLs) or protein levels (pQTLs) within each 99% credible set for all
new and previously reported signals outside the HLA region (Online Methods).
There were 25 SNPs, located in 22 unique genes, which were annotated as potentially deleterious
(Online Methods, Supplementary Table 11). Amongst our new signals, there were 10 variants
annotated as deleterious in 9 different genes: DOCK9 (rs117633128), CEP72 (rs12522955), BCHE
(rs1799807), DST (rs11756977), KIAA0753 (rs2304977, rs9889363), LRRC45 (rs72861736), BTC
(rs11938093), C2orf54 (rs6709469) and IER5L (rs184457). Of these, the missense variant in BCHE
(rs1799807) had the highest posterior probability (0.996) in its respective credible set, was low
frequency (MAF=1.95%) and resulted in an amino acid change from aspartic acid (D) to glycine (G),
known to affect the function of the encoded butyrylcholinesterase enzyme by altering substrate
binding26. The two common missense variants in KIAA0753 were within the credible set of new
signal rs4796334. KIAA0753, CEP72 and LRRC45 all encode proteins with a role in ciliogenesis or cilia
maintenance27-31, and all are highly expressed in the airway epithelium32.
Variants in the 99% credible sets were queried in three eQTL resources to identify associations with
gene expression in lung33-35 (sample size n=1,111; Supplementary Table 12), blood36 (n=4,896) and a
subset of GTEx37 tissues (max n=388, Online Methods). The tissues included from GTEx were lung
and blood, plus nine tissues known to contain smooth muscle (Online Methods). The latter were
chosen based on previous reports of enrichment of lung function GWAS signals in smooth muscle-
containing tissues18,38. We identified 88 genes, implicated by 58 of the 279 signals, for which the
most significant SNP associated with expression of that gene in the respective eQTL resource was
within one of the 99% credible sets (Supplementary Table 13).
We checked credible set variants for association with protein levels in a pQTL study39 comprising SNP
associations for 3,600 plasma proteins (Online Methods). We found 5 proteins with a sentinel pQTL
contained within our lung function credible set: ECM1, THBS4, NPNT, C1QTNF5 and SCARF2
(Supplementary Table 14).
In total, 107 putative causal genes were identified (Table 1), amongst which, we highlight 75 for the
first time as putative causal genes for lung function (43 implicated by a new signal and 32 newly
implicated by a previous signal18).
8Pathway analysis
We tested whether these 107 putative causal genes were enriched in gene sets and biological
pathways (Online Methods), finding an enrichment of genes in elastic fibre and extracellular matrix
organisation pathways, and a number of gene ontologies including gene sets relating to the
cytoskeleton and processes involved in ciliogenesis (Supplementary Table 15). Whilst the
enrichment in elastic fibre-related pathways is consistent with our previous study18, enrichment in
these pathways was further supported in this analysis by two new genes, ITGAV (at a new signal) and
GDF5 (a newly implicated gene for a previously reported signal), and by strengthened eQTL evidence
for TGFB2 and MFAP2 at two previously reported signals. The presence of TGFB2, GDF5 and SMAD3
in our list of 107 genes resulted in enrichment of a TGF-β superfamily signalling pathway (TGF-Core) 
and related gene ontology terms (Supplementary Table 15).
Functional enrichment analyses
Using stratified LD-score regression,40 we showed that FEV1/FVC and FVC heritability is significantly
enriched at variants overlapping histone marks that are specific to lung, foetal lung, and smooth
muscle-containing (i.e. colon and stomach) cell lines. SNPs that overlap with H3K4me1 marks that
are specific to foetal lung cells correspond to 6.99% of the input SNPs yet explain 57.09% (P=2.85x10-
25) and 35.84% (P=4.19x10-21) of the SNP-chip heritability for FEV1/FVC and FVC, respectively
(Supplementary Table 16).
We also tested enrichment of (i) FEV1/FVC and (ii) FVC SNPs at DNase I hypersensitive site (DHS)
hotspots using GARFIELD41 (Online Methods). For FEV1/FVC results, we see significant enrichment
across most cell lines with increased fold-enrichment in foetal and adult lung, foetal muscle and
fibroblasts (Supplementary Figure 4A). For FVC, we see similar broad significant enrichment without
evidence of increased enrichment in a subset of tissues (Supplementary Figure 4B). This suggests
that SNPs influencing FVC may act via more complex and broader developmental pathways.
We used DeepSEA42 to identify whether our signals were predicted to have a chromatin effect in
lung-related cell lines. We identified 10 signals (including 5 new signals) for which the SNP with the
largest posterior probability of being causal also had a significant predicted effect on a DHS in lung-
related cells (Supplementary Table 17). This included a new signal near SMURF2 (17q24.1,
rs11653958).
Drug targets
All 107 putative causal genes were investigated for known gene-drug interactions43 (Supplementary
Table 18). We highlight two examples of new genetic signals implicating targets for drugs in
development for indications other than COPD. One of our new signals is an eQTL for ITGAV. ITGAV
encodes a component of the αvβ6 integrin heterodimer, which is inhibited by a monoclonal antibody 
in development for pulmonary fibrosis (NCT01371305) and for which the small molecule
GSK3008348 (NCT03069989) is an antagonist44. Integrins have an emerging role as local activators of
TGFβ and specifically the avb6 integrin heterodimer can activate latent-TGFβ45. In our study, the
allele associated with reduced expression of ITGAV (Supplementary Table 13) was associated with
increased lung function (Supplementary Table 9) suggesting that inhibitors of αvβ6 integrin might 
also have a beneficial effect in COPD. Another of our new signals is associated with expression of
TNFSF13 (synonym APRIL), a cytokine of the TNF ligand family. Atacicept blocks B cell stimulation by
TNFSF13 (as well as by BLyS) and reduced systemic lupus erythematosus disease activity in a recent
9Phase IIb trial46. In our study, the allele associated with decreased expression of TNFSF13 was
associated with reduced FEV1, indicating that vigilance for pulmonary consequences of atacicept
may be warranted.
Genetic Risk Score: association with FEV1/FVC and COPD in multiple ancestries
We constructed a genetic risk score (GRS) weighted by FEV1/FVC effect sizes comprising all 279
sentinel variants, and tested for association with FEV1/FVC and GOLD Stage 2-4 COPD (FEV1/FVC<0.7
and FEV1<80% predicted) in different ancestry groups in UK Biobank, and China Kadoorie Biobank
(Online Methods, Supplementary Table 19). UK Biobank participants of non-European ancestry
were not included in the discovery analyses. The GRS was associated with a significant decrease in
lung function, and corresponding significant increase in COPD risk in each of the independent
ancestry groups (Figure 3a).
We tested for a GRS interaction with smoking in European ancestry individuals in UK Biobank47. No
statistical interaction was seen for FEV1/FVC (interaction term -0.002 per SD change in GRS, 95% CI:
[0.009, 0.005], P=0.532), whilst the findings for COPD were consistent with a slightly smaller effect of
the GRS in ever-smokers (OR for ever-smoking-GRS interaction term per SD change in GRS 0.96, 95%
CI: [0.92, 0.99], P=0.015).
The association of the GRS with COPD susceptibility was additionally tested in five independent
COPD case-control studies (Supplementary Table 20, Online Methods). Similar effect size estimates
were seen across each of the 5 European ancestry studies (Figure 3b); in the meta-analysis of these
studies (n=6,979 cases and 3,915 controls), the odds ratio for COPD per standard deviation of the
weighted GRS was 1.55 (95% CI: [1.48, 1.62]), P=2.87×10-75 (Supplementary Table 21). The GRS was
also associated with COPD in individuals of African-American ancestry in COPDGene (P=8.36×10-7),
albeit with a smaller effect size estimate, odds ratio=1.26 (95% CI: [1.15, 1.37]).
To aid clinical interpretation, we divided individuals in each of the five European ancestry COPD
case-control studies into deciles, according to their value of the weighted GRS. The odds ratio for
COPD in members of the highest GRS decile compared to the lowest GRS decile was 4.73 (95% CI:
[3.79, 5.90]), P=3.00×10-43 (Figure 3c, Supplementary Table 22). We calculated the population
attributable risk fraction (Supplementary Note) and estimated that the proportion of COPD cases
attributable to risk scores above the first GRS decile was 54.6% (95% CI: [50.6%, 58.4%]).
Incorporation of the GRS into a risk model already comprising available clinical information (age, sex,
height and pack-years of smoking in COPDGene non-Hispanic Whites) led to a statistically significant
(P=3.33×10-10), yet modest, increase in the area under the curve, from 0.751 to 0.771
(Supplementary Note). Based on our estimated GRS relative risk and absolute risk estimates of
COPD48, one would expect the highest GRS risk decile group of smokers to have an absolute risk of
developing COPD by approximately 70 years of age of 82.4%, versus 17.4% for the lowest GRS decile
(Supplementary Note).
Pleiotropy and phenome-wide association studies
As phenome-wide association studies (PheWAS) can provide evidence mimicking pharmacological
interventions of drug targets in humans and informing drug development49, we undertook a PheWAS
of 2,411 phenotypes in UK Biobank (Online Methods, Figure 4, Supplementary Table 23); 226 of the
279 sentinel variants were associated (FDR<1%) with one or more traits and diseases (excluding
quantitative lung function traits). Eighty-five of the lung function signals were associated with
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standing height. In order to investigate whether the genetic association signals for lung function
were driven by incomplete adjustment for height, we tested for correlation of effects on lung
function in UK Biobank and height in a meta-analysis of UK Biobank and the GIANT consortium for
246 of the 279 signals that had a proxy variant in GIANT50; there was no significant correlation
(Supplementary Figure 5). Additionally, the PheWAS revealed associations with body composition
measures such as fat free mass (54 SNPs) and hip circumference (40 SNPs), as well as muscle
strength (32 SNPs, grip strength). One hundred and fourteen of the 279 SNPs were associated with
several quantitative measures of blood count, including eosinophil counts and percentages (25
SNPs). Twenty-five of our SNPs were also associated with asthma including 12 SNPs associated both
with asthma and eosinophil measures (Supplementary Table 24). Eight of these SNPs were in LD
(r2>0.1) with a SNP reported for association with asthma in previously published genome-wide
association studies. We compared our observed effect sizes with those estimated after exclusion of
all self-reported asthma cases and observed similar estimates (Supplementary Figure 6) suggesting
that the lung function associations we report are not driven by asthma.
We examined the specificity of genetic associations, given the potential for this to predict specificity
of drug target modification, and found that 53 of the 279 signals were associated only with lung
function and COPD-related traits. In contrast, three of our 279 signals were associated with over 100
traits across multiple categories – among these rs3844313, a known intergenic signal near HLA-DQB1
was associated with 163 traits, and also had the strongest signal in the PheWAS, which was for
association with intestinal malabsorption and coeliac disease.
In our 279-variant weighted GRS PheWAS analysis (Supplementary Table 25), we found association
with respiratory traits including COPD, chronic bronchitis, emphysema, respiratory failure,
corticosteroid use and both paediatric and adult-onset asthma (Figure 5a). The GRS was also
associated with non-respiratory traits including coeliac disease, an intestinal autoimmune disorder
(Figure 5b). These pleiotropic effects on risk of autoimmune diseases was further confirmed by
analysis of previously reported GWAS (Online Methods, Supplementary Table 26) which showed
overlapping single variant associations with Crohn’s disease, ulcerative colitis, psoriasis, systemic
lupus erythematosus, IgA nephropathy, pediatric autoimmune disease and type 1 diabetes.
Discussion
The large sample size of our study, achieved by our refinement of the spirometry in UK Biobank and
inclusion of the substantially expanded SpiroMeta consortium data set, has doubled the yield of lung
function signals to 279. Fine-mapping of all new and previously reported signals, together with gene
and protein expression analyses with improved tissue specificity and stringency, has implicated new
genes and pathways, highlighting the importance of cilia development, TGF-β signalling via SMAD3, 
and elastic fibres in the aetiology of airflow obstruction. Many of the genes and pathways reported
here contain druggable targets; we highlight examples where the genetic variants mimicking
therapeutic modulation of targets may have opposing effects on lung function. We have developed
and applied the first weighted GRS for lung function and tested it in independent COPD case-control
studies. Our GRS shows stronger association and larger effect size estimates than a previous GRS in
European ancestry populations18, as well as generalisability to other ancestry groups. We undertook
the first comprehensive PheWAS for lung function signals, and report genetic variants with apparent
specificity of effects and others with pleiotropic effects that might indicate shared biological
pathways between different diseases.
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For the first time in a GWAS of lung function, we report an enrichment of genes involved in
ciliogenesis (including KIAA0753, CDK2 and CEP72). Defects in primary cilia as a result of highly
deleterious mutations in essential genes result in ciliopathies known to affect multiple organ
systems. We found an enrichment of genes with a role in centriolar replication and duplication, core
processes in primary and motile cilia formation. Mutations in KIAA0753 cause the ciliopathies
Joubert Syndrome and Orofaciodigital Syndrome28. Reduced airway motile cilia function impacting
mucus clearance is a feature of COPD, but it has not been clear whether this is causal or the
consequence of damage by external factors such as smoking or infection. Our findings suggest that
impaired ciliary function might be a driver of the disease process. We have previously shown
enrichment of rare variants in cilia-related genes in heavy smokers without airflow obstruction51.
New signals, implicating ITGAV and GDF5, as well as stronger support for TGFB2 and MFAP2 as likely
causal genes, provide new genetic support for the importance of elastic fibre pathways in lung
function and COPD18. The elastic fibres of the extracellular matrix are known to be disrupted in
COPD52. As the breakdown of elastic fibres by neutrophil elastase leads to emphysema in individuals
with alpha1-antitrypsin deficiency, we also assessed the association with the SERPINA1 Z allele,
which was not associated with FEV1/FVC in our study (rs28929474, P=0.109 in UK Biobank).
Smoking and genetic risk both have important effects on lung function and COPD. For lung function,
we found no interaction between smoking and individual variants, and for FEV1/FVC no interaction
between smoking status and the weighted GRS. However, for COPD a weak smoking-GRS interaction
was observed. Whilst the weighted GRS showed a strong association with COPD susceptibility, and a
high attributable risk, we do not claim that this would represent an appropriate method of screening
for COPD risk. Importantly, our findings demonstrate the high absolute risk among genetically
susceptible smokers (82.4% by approximately 70 years of age).
The unprecedented sample size of UK Biobank as a single cohort has revolutionised genetic studies.
We used two complementary study designs to maximise sample size for discovery and ensure
robustness of findings by requiring independent support for association. Furthermore, through
additional analysis of the spirometry data in UK Biobank and substantial expansion of the SpiroMeta
consortium, we have markedly increased samples sizes to almost seven times those included in
previous studies. As no lower MAF threshold was applied in our analyses, an overall threshold of
P<5×10-9, as recommended for re-sequencing analyses of European ancestry individuals23, was
applied. We identified the largest number of new signals in our more stringent two-stage design
(“Tier 1”, 99 new signals). Amongst the signals that we report as “Tier 3” (and did not include in
further analyses), all reached P<10-3 in UK Biobank and 183 met a less stringent threshold of P<0.05
in SpiroMeta. As the primary objective of our paper was to identify variants that were robustly
associated with lung function and COPD; we did not include the Tier 3 signals in the downstream
analyses. However, as a GRS based on fuller sets of variants are likely to add power for genetic
prediction, we have made available our Tier 3 signals (and genome-wide findings) to the scientific
community.
Our study is the first to investigate genome-wide associations with PEF. PEF is determined by various
physiological factors including lung volume, large airway calibre, elasticity of the lung and expiratory
muscle strength, is used for monitoring asthma, and was incorporated in a recently evaluated clinical
score for diagnosing COPD and predicting acute exacerbations of COPD53. Overall, 133 of the 279
signals were also associated with PEF (P<10-5) and for 15 signals (including 4 new signals), PEF was
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the most significantly associated trait. Of note, a signal near SLC26A9, a known cystic fibrosis
modifier gene54, was highly significantly associated with PEF in UK Biobank (P=3.97×10-66) and
nominally significant in SpiroMeta (P=6.93×10-3), with consistent direction of effect, but did not meet
the Tier 2 criteria. This could reflect the limited power for PEF in SpiroMeta (up to 24,218 for PEF
compared to 79,055 for the other traits).
Examining associations of a given genetic variant with a wide range of human phenotypes is a
valuable tool in therapeutic target validation. As in our PheWAS, it can highlight variants which show
associations with one or more respiratory traits that might be expected to demonstrate greater
target specificity than variants associated with many traits. Additionally, in some instances,
association with multiple traits may indicate the relevance of drug repurposing. Association of a
given SNP with multiple traits does not necessarily imply shared aetiology, and further investigation
is warranted. Our GRS PheWAS assesses broader genetic overlap between lung function and other
traits and supports the evidence for some shared genetic determinants with autoimmune diseases.
Our study did not assess interaction of the signals with factors other than smoking, further studies
might include assessments for interaction effects, for example, with sex, air pollution and dietary
intake. We did not analyse variants on the sex chromosomes as those data were not available at the
time of our study.
In summary, our study has doubled the number of signals for lung function and provides new
understanding and resources of utility for the development of therapeutics. The 279-variant GRS we
constructed was associated with a 4.73-fold increased relative risk of moderate-severe COPD
between highest and lowest deciles, such that one would expect over 80% of smokers in the highest
genetic risk decile to develop COPD. The GRS was also predictive of COPD across multiple ancestral
groups. Our PheWAS highlights both expected and unexpected associations relevant to respiratory
and other systemic diseases. Investigating the nature of the pleiotropic effects of some of these
variants will be of benefit for drug target identification and validation.
Online Methods
Study Design Overview and rationale
For the two-stage approach, we firstly selected distinct signals of association (defined using
conditional analyses) with one or more traits achieving P<5×10-9 in UK Biobank only (n up to
321,047). A threshold of P<5×10-9 was selected to maximise stringency of findings and to be
consistent with currently recommended genome-wide significance thresholds for re-sequencing
analyses of European ancestry individuals23. We then reported as new those signals which
additionally met P<10-3 in SpiroMeta (N effective>70% of n up to 79,055; see Supplementary Note
and Supplementary Figure 7 for power calculations), with consistent directions of effect and term
them “Tier 1“ signals as they meet our highest level of stringency. Methods for conditional analyses
and determining novelty are described below.
For the one-stage approach, we selected distinct signals of association (defined using conditional
analyses) with one or more traits reaching P<5×10-9 in the meta-analysis of UK Biobank and
SpiroMeta (n up to 400,102) and reported as new those which additionally met P<10-3 in both UK
Biobank and SpiroMeta with a consistent direction of effect. We term these signals “Tier 2“ as they
meet our second-highest level of stringency.
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All signals meeting either set of criteria described above, and that had not been previously
published, were reported as new signals of association with lung function. Signals that reached
P<5×10-9 in the meta-analysis of UK Biobank and SpiroMeta, had a consistent direction of effect in
UK Biobank and SpiroMeta, but which did not reach P<10-3 in both UK Biobank and SpiroMeta are
presented as “Tier 3” and were not included in further analyses.
Data for chromosome X were available for 321,027 European individuals in UK Biobank and 38,199
individuals from SpiroMeta (1000 Genomes Project Phase 1 imputation).55
UK Biobank
The UK Biobank data resource is described elsewhere (http://www.ukbiobank.ac.uk). Individuals
were selected for inclusion in this study if they met the following criteria: (i) had complete data for
age, sex, height and smoking status; (ii) had spirometry meeting quality control requirements (based
on analyses of acceptability, reproducibility and blow curve metrics; Supplementary Note); (iii) had
genome-wide imputed genetic data and; (iv) were of European ancestry based on genetic data
(Supplementary Note; Supplementary Figure 1). Genotyping was undertaken using the Affymetrix
Axiom® UK BiLEVE and UK Biobank arrays13. Genotypes were imputed to the Haplotype Reference
Consortium panel56 (Supplementary Note), and retained if minor allele count≥3 and imputation 
quality (info)>0.5. A total of 321,047 individuals were included in this analysis (Supplementary Table
1).
Residuals from linear regression of each trait (FEV1, FVC, FEV1/FVC and PEF) against age, age2, sex,
height, smoking status (ever/never) and genotyping array were ranked and inverse-normal
transformed to obtain adjusted, normally distributed Z-scores. These Z-scores were then used for
genome-wide association testing under an additive genetic model using BOLT-LMM v2.320. Principal
components were not included as BOLT-LMM uses a linear mixed model to account for relatedness
and fine-scale population structure.
Linkage disequilibrium (LD) score regression implemented in LDSC21 was used to estimate inflation of
test statistics due to confounding. Genomic control was applied, adjusting all test statistics by LD
score regression intercepts: 1.12 for FEV1, 1.14 for FVC, 1.19 for FEV1/FVC and 1.13 for PEF
(Supplementary Figure 8; Supplementary Table 27), acknowledging that this might be over-
conservative for UK Biobank.
SpiroMeta consortium
The SpiroMeta consortium meta-analysis was comprised of a total of 79,055 individuals from 22
studies. Thirteen studies (n=21,436 individuals) were imputed to the 1000 Genomes Project Phase 1
reference panel55 (B58C, BHS1&2, three Croatian studies [CROATIA-Korcula, CROATIA-Split and
CROATIA-Vis], Health 2000, KORA F4, KORA S3, LBC1936, NSPHS, ORCADES, SAPALDIA and YFS) and 9
studies (n=61,682 individuals) were imputed to the Haplotype Reference Consortium (HRC) panel57
(EPIC [obese cases and population-based studies], GS:SFHS, NFBC1966, NFBC1986, PIVUS, SHIP,
SHIP-TREND, UKHLS and VIKING). See Supplementary Tables 2 and 3 for the definitions of all
abbreviations, study characteristics, details of genotyping platforms and imputation panels and
methods). Measurements of spirometry for each study are described in the Supplementary Note.
In each study, linear regression models were fitted for each lung function trait (FEV1, FEV1/FVC, FVC
and PEF, where available), with adjustment for age, age2, sex and height. For studies with unrelated
individuals, these models were fitted separately in ever smokers and never smokers, with additional
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adjustment for principal components of ancestry. Studies with related individuals fitted mixed
models in all individuals to account for relatedness, with ever smoking status as a covariate.
In all studies, rank-based inverse normal transformations were undertaken on the residuals, with
these transformed residuals used as the phenotype for association testing under an additive genetic
model (Supplementary Table 3).
In the study level results, variants were excluded if they had a very low minor allele count (MAC)
(Supplementary Table 3) or imputation quality (info)<0.3. In studies with unrelated individuals, the
ever and never smokers results were combined, using inverse variance weighted meta-analysis, to
give an overall study result. Genomic control was then applied to all study level results, before
combining results across all studies using inverse variance weighted meta-analysis. LD score
regression intercepts for the meta-analysis were close to 1.00 (Supplementary Figure 8;
Supplementary Table 27) and so genomic control was not applied.
Meta-analyses
A total of 19,871,028 variants (imputed or genotyped) in both UK Biobank and SpiroMeta were
meta-analysed using inverse-variance weighted fixed effect meta-analysis, and no further genomic
control was applied as LD score regression intercepts were close to 1.00 (Supplementary Table 27).
Selection of new signals using conditional analyses
All SNPs ±1Mb were extracted around each sentinel variant. GCTA58 was then used to perform
stepwise conditional analysis to select independently associated SNPs within each 2Mb region. LD
was estimated for UK Biobank from the same individuals used in discovery, and for SpiroMeta, from
an unrelated subset of 48,943 UK Biobank individuals18. Any secondary signals identified within each
2Mb region were required to meet Tier 1 or Tier 2 criteria (described above) after conditioning on
the primary sentinel variant. A combined list of distinct lung function signals was then made across
the 4 phenotypes, FEV1, FVC, FEV1/FVC and PEF as follows: where sentinel variants for 2 signals for
different phenotypes were in high LD (r2>0.5), we retained the most significant variant; where 2
signals were in moderate LD (0.1>r2>0.5), we retained variants if, after conditional analysis, they still
met the Tier 1 or Tier 2 threshold; for signals in low LD (r2<0.1) we retained both variants. We then
used the same criteria to identify a subset of new signals which were distinct from previously
published independent signals (see below).
Assessment of previously reported lung function signals
We identified 184 autosomal signals from previous GWAS analyses of lung function and COPD1,4-14.
After LD pruning (keeping only those signals with LD of r2<0.1), we removed 24 non-independent
SNPs, leaving 160 previously reported independent signals. Of 6 previously reported signals in the
HLA region, we included only the 3 independent lung function HLA signals reported from conditional
analysis using all imputed HLA genotypes18: AGER (rs2070600), HLA-DQB1 (rs114544105) and near
ZNF184 (rs34864796) leaving 157 signals.
We confirmed association of previously reported signals in our data if they met any of three criteria:
(i) the previously reported sentinel was associated (P<10-5) with any lung function trait in UK
Biobank; (ii) a proxy for the previously reported sentinel with r2>0.5 was associated (P<10-5) with any
lung function trait in UK Biobank; (iii) a proxy for the previously reported sentinel with r2>0.1 was
associated with any lung function trait meeting tier 1 or tier 2 criteria (Supplementary Figure 3).
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Effect on COPD susceptibility – genetic risk score in multiple ancestries
To test association of all lung function signals and COPD susceptibility, we constructed a 279-variant
weighted GRS comprising the 139 novel and 140 previously reported signals; we used the previously
reported sentinel SNP for published signals. Weights were derived using the FEV1/FVC ratio
decreasing (COPD risk increasing) alleles. For previously reported signals (n=140), results from the
UK Biobank analysis were used to derive weights for the 94 signals that were not discovered using
UK Biobank data and weights were taken from SpiroMeta for 46 signals where UK Biobank was
included in the discovery of those signals. For novel signals identified in this study, weights were
taken from SpiroMeta for two-stage (tier 1) signals (n=99), and the smallest absolute effect size from
either of UK Biobank or SpiroMeta was used for one-stage (tier 2) signals (n=40) (Supplementary
Table 28). This approach was taken in order to derive conservative weights for each variant, thus
reducing the likelihood of bias by winner’s curse. For the weighted GRS the number of risk alleles at
each variant was multiplied by its weight.
The GRS was first calculated in unrelated individuals (KING kinship coefficient of<0.0884) within 6
ancestral groups of UK Biobank: Europeans, South Asians, Africans, Chinese, Mixed African and
Europeans, and Mixed Other (total sample of unrelated individuals across six ancestries: 323,001)
using PLINK. Weights and alleles were as described above. COPD was defined as FEV1/FVC<0.7 and
FEV1<0.8 of the predicted value, i.e. GOLD stage 2-4 categorisation. Associations with the GRS were
then tested using COPD (in ancestral groups with at least 100 COPD cases) and FEV1/FVC as the
outcomes.
In addition, we calculated the GRS in individuals from the China Kadoorie Biobank (CKB). Four of the
279 SNPs were not available in CKB (rs1800888, rs56196860, rs72724130 and rs77672322), and for
12 SNPs, proxies were used (minimum r2=0.3). Analyses were undertaken in all COPD GOLD stage 2-4
cases (FEV1/FVC<0.7 and FEV1<0.8 of the predicted value, in 6,013 cases and 69,567 controls),
against an unbiased set of population controls. The GRS was also tested for association with
FEV1/FVC in CKB (n=72,796).
Logistic regression of COPD case-control status with the GRS in UK Biobank and China Kadoorie
Biobank assumed an additive genetic effect and was adjusted for age, age2, sex, height, and smoking
(Supplementary Table 19). Ten principal components were also included in UK Biobank analyses. In
China Kadoorie Biobank, analyses were stratified by geographical regions and then meta-analysed
using an inverse-variance fixed effect model. Linear models assessing the association with FEV1/FVC
were fitted using the same transformed outcome as in the main GWAS analysis.
We then tested association in 5 European ancestry COPD case-control studies: COPDGene (Non-
Hispanic White Population) (3,068 cases and 2,110 controls), ECLIPSE (1,713 cases and 147 controls),
GenKOLS (836 cases and 692 controls), NETT-NAS (374 cases and 429 controls) and SPIROMICS (988
cases and 537 controls) (Supplementary Table 20). In addition, we tested this GRS in the COPDGene
African American population study (910 cases and 1,556 controls). Logistic regression models using
COPD as outcome and the GRS as exposure were adjusted for age, age2, sex, height, and principal
components (Supplementary Table 21, Supplementary Figure 9). Single variant associations of the
279 SNPs with COPD are in Supplementary Table 29.
Next, we divided individuals in the external COPD case-control studies into deciles according to their
values of the weighted GRS. This was undertaken separately by study group, and for each decile
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logistic models were fitted, comparing the risk of COPD for members of each decile group compared
to those in the lowest decile (i.e. those with lowest values of the weighted GRS). Covariates were as
for the COPD analyses. Results were combined across European-ancestry study groups by fixed
effect meta-analysis (Supplementary Table 22).
Effects on smoking behaviour
As our discovery GWAS in UK Biobank was adjusted for ever vs. never smoking status, and not for
pack years of smoking (pack years information was missing for 32% of smokers), we evaluated
whether any signals of association with lung function might be driven by an association with smoking
behaviour by testing for association with smoking initiation (123,890 ever smokers vs. 151,706 never
smokers) and cigarettes per day (n=80,015) in UK Biobank (full methods in Supplementary Note).
We also tested for association with lung function in never smokers only (n=173,658). We excluded
any signals associated with smoking behaviour (Supplementary Table 6), but not with lung function
in never smokers.
Smoking interaction
For associated variants (new and previously reported), we repeated association testing for lung
function separately in UK Biobank and SpiroMeta (up to 176,701 ever smokers and 197,999 never
smokers), and tested for an interaction effect with smoking using the Welch test (Supplementary
Note). A threshold of P<1.79×10-4 (Bonferroni corrected for 279 tests) indicated significance.
We further tested for interaction between the weighted GRS and smoking, within 303,619 unrelated
individuals of European ancestry in UK Biobank, using COPD and FEV1/FVC as outcomes (the
FEV1/FVC phenotype was pre-adjusted for age, age2, sex, and height, and the residuals transformed
as per the main GWAS analysis). For COPD (defined as FEV1/FVC<0.7, and FEV1<80% predicted) the
following logistic model was fitted:
COPD ~ genotyping array + 10 principal components + age + age2 + sex + height + smoking status +
weighted risk score + (smoking status × weighted risk score).
For FEV1/FVC the following linear model was fitted:
FEV1/FVC ~ genotyping array + 10 principal components + smoking status + weighted risk score +
(smoking status x weighted risk score).
Proportion of variance explained
We calculated the proportion of variance explained by each of the previously reported (n=140) and
new variants (n=139) associated with lung function using the formula:
∑ 2     (1 −     )           
 
where n is the number of variants fi and βi are the frequency and effect estimate of the i’th variant,
and V is the phenotypic variance (always 1 as our phenotypes were inverse-normal transformed).
We used the same conservative effect estimates (β) as used to calculate GRS weights at the same set 
of 279 sentinel variants used for the GRS, which uses either UK Biobank or SpiroMeta effect
estimates (described above). Our previously published estimate of proportion of variance
explained18 used effect estimates derived from UK Biobank. We assumed a heritability of 40%24,25 to
estimate the proportion of additive polygenic variance.
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Fine-mapping
A Bayesian method59 was used to fine-map lung-function-associated signals to the set of variants
that were 99% likely to contain the underlying causal variant (assuming that the causal variant has
been analysed). This was undertaken for new signals and for previously reported signals reaching
P<10-5 in UK Biobank. For the previously reported signals, the top sentinel variant from the current
analysis in UK Biobank was used, instead of the previously reported variant. We used a value of 0.04
for the prior W in the approximate Bayes factor formula60. Effect sizes and standard errors for fine-
mapping were obtained from an inverse variance weighted meta-analysis of UK Biobank and
SpiroMeta (n up to 400,102). Signals in the HLA region were not included.
Implication of potentially causal genes
Annotation of deleterious variants
Variants in the 99% credible sets were checked for predicted functional effect if they were
annotated as “exonic”, “splicing”, “ncRNA_exonic”, “5’-UTR” or “3’-UTR” (untranslated region) by
ANNOVAR61. We then used SIFT, PolyPhen-2 (implemented using the Ensembl GRCh37 Variant
Effect Predictor, https://www.ensembl.org/vep, accessed 1 February 2018) and FATHMM62 to
annotate missense variants, and CADD (also implemented using VEP) to annotate non-coding
variation. Variants were annotated as deleterious in our study if they were labelled 'deleterious' by
SIFT, 'probably damaging' or 'possibly damaging' by PolyPhen-2, ‘damaging’ by FATHMM (specifying
the ‘Inherited disease’ option of the coding variants methods, and setting the prediction algorithm
to ‘Unweighted’) or had a CADD scaled score ≥204. The union of the four methods was taken to
establish the number of potentially deleterious variants and their unique genes.
Gene expression and protein levels
At 276 of 279 (3 HLA signals excluded) signals, the sentinel variant and 99% credible set59 were used
to query three eQTL resources: lung eQTL (n=1,111)13, blood eQTL (n=4,896)63 and GTEx (V7; with n
up to 388 depending on tissue: Artery Aorta (n=267), Artery Coronary (n=152), Artery Tibial (n=388),
Colon Sigmoid (n=203), Colon Transverse (n=246), Esophagus Gastroesophageal Junction (n=213),
Esophagus Muscularis (n=335), Lung (n=383), Small Intestine Terminal Ileum (n=122), Stomach
(n=237), and Whole Blood (n=369))64, and one blood pQTL resource (n=3,301)39.
A gene was classified as a ‘putative causal gene’ if the sentinel SNP or any SNP in the respective 99%
credible set was associated with expression of this gene or its protein levels (FDR<5% for eQTL,
P<5.03×10-8 [for 276 tests at 3,600 proteins] for pQTL) and if the GWAS sentinel SNP or any SNP in
the respective 99% credible set was also the variant most strongly associated with expression of the
respective gene or level of the respective protein (i.e. the sentinel eQTL/pQTL SNP) in one or more of
the eQTL and pQTL data sets.
Pathway analysis
We tested for enrichment of genes identified via variant function annotation, gene expression or
protein level analyses in pathway and gene set ontology databases using ConsensusPathDB.65
Pathways or gene sets represented entirely by genes implicated by the same association signal were
excluded. Gene sets and pathways with FDR<5% are reported.
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Functional enrichment analyses
We carried out stratified LD score regression to identify significant enrichment of heritability at
variants overlapping histone marks (e.g. H3K4me1, H3K4me3) that are specific to lung, foetal lung,
and smooth muscle containing (i.e. colon, stomach) cell lines using methods specified by Finucane et
al.40
We separately selected FEV1/FVC and FVC associated SNPs passing two thresholds (P<5×10-5 and
P<5×10-9 in the meta-analysis) as input to GARFIELD41 to test for enrichment of our signals for 424
DHS hotspot annotations derived from 55 different tissues in the RoadMap Epigenomics project and
the ENCODE projects.
Using DeepSEA42, we analysed all SNPs in the 99% credible set for predicted chromatin effects. We
reported effects for any chromatin effect and lung-related cell line that had an E-value<0.05 (i.e. the
expected proportion of SNPs with a larger predicted effect based on empirical distributions of
predicted effects for 1000 Genomes SNPs) and an absolute difference in probability of>0.1
(threshold for “high confidence”) between the reference and alternative allele.
Drug targets
Genes identified as potentially causal using eQTL, pQTL or variant annotation were interrogated
against the gene-drug interactions table of the Drug-Gene Interactions Database (DGIDB)
(http://www.dgidb.org/data/), accessed 16th October 2017. Drugs were mapped to CHEMBL IDs
(https://www.ebi.ac.uk/chembl/drug/indications), and indications (as MeSH headings) were added.
Phenome-wide association studies
To identify whether the 279 signals overlap with signals of association for other traits and diseases,
the weighted GRS was calculated in up to 379,337 UK Biobank samples, and a phenome-wide
association study (PheWAS) was performed, with the GRS as the exposure. Traits included UK
Biobank baseline measures (from questionnaires and physical measures), self-reported medication
usage, and operative procedures, as well as those captured in Office of Population Censuses and
Surveys codes from the electronic health record. We also included self-reported disease variables
and those from hospital episode statistics (ICD-10 codes truncated to three-character codes and
combined in block and chapter groups), combining these where possible to maximise power. The
GRS analysis included 2,453 traits, and the single-variant analysis contained 2,411 traits (traits
with>200 cases were included for the single-variant PheWAS, whereas traits with>50 cases were
included in the GRS PheWAS). Analyses were conducted in unrelated European-ancestry individuals
(KING kinship coefficient <0.0442), and were adjusted for age, sex, genotyping array, and ten
principal components. Logistic and linear models were fitted for binary and quantitative outcomes,
respectively. False discovery rates were calculated on the basis of the number of traits in the GRS
and single-variant PheWAS (2,453 or 2,411, respectively).
In addition, the sentinel variants and variants within the 99% credible sets were queried against the
GWAS catalog66 (https://www.ebi.ac.uk/gwas/, accessed 5th February 2018) and GRASP67
(https://grasp.nhlbi.nih.gov/Overview.aspx, accessed 6th February 2018) for associations reported
at P<5×10-8. Associations relating to methylation, expression, metabolite or protein levels, as well as
lung function and COPD, were not included.
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Figures and Figure Legends
Figure 1: Study design
Tier 1 signals had P<5×10-9 in UK Biobank and P<10-3 in SpiroMeta with consistent direction of effect.
Tier 2 signals had P<5×10-9 in the meta-analysis of UK Biobank and SpiroMeta with P<10-3 in UK Biobank and P<10-3 in
SpiroMeta with consistent directions of effect. Signals with P<5×10-9 in the meta-analysis of UK Biobank and
SpiroMeta, and that had consistent directions of effect but did not meet P<10-3 in both cohorts were reported as Tier
3.
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Figure 2: Strength and direction of association across four lung function traits for 139 novel signals: Signals are in chromosome and genomic position order from top to
bottom then left to right. Red indicates a decrease in the lung function trait; blue indicates an increase. All effects are aligned to the allele associated with decreased
FEV1/FVC, hence the FEV1/FVC column is only red or white. P-values are from the meta-analysis of UK Biobank and SpiroMeta (n=400,102). The scale points are thresholds
used for (i) confirmation in 2-stage analysis and 1-stage analysis (P<10-3); (ii) confirmation of association of previous signals (P<10-5); (iii) signal selection in 2-stage and 1-
stage analysis (P<5×10-9); capped at (P<10-20).
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Figure 3: Association of weighted genetic risk score (GRS) with COPD and FEV1/FVC.
A. Association of the weighted genetic risk score (GRS) with FEV1/FVC and COPD in UK Biobank and China
Kadoorie Biobank (CKB). For means and standard deviations of the risk scores in each group, see
Supplementary Table 19. The left-hand axis denotes change in standard deviation (SD) units of FEV1/FVC per
1 SD increase in weighted GRS (blue bars). The right axis shows the translation of this effect to COPD in the
same individuals, defined as FEV1/FVC<0.7 and FEV1<0.8 of the predicted value, i.e. GOLD stage 2-4
categorisation. Odds ratios (OR) for COPD (red bars) are given per 1 standard deviation (SD) increase in
weighted GRS (OR for COPD shown only for ancestries in UK Biobank with>100 cases of COPD). Bars are
labelled with ancestral groups, and the total sample size and number of COPD cases are given. The height of
the bars represents the effect estimate, and the black whiskers represent 95% confidence intervals. Note
some variants included in the GRS were discovered in UK Biobank individuals of European ancestry, and
therefore the results for UKB Europeans (far left bars, greyed out) are shown for reference only. All other
ancestral groups shown in the plot are independent to UK Biobank Europeans. There were 13 SNPs with
MAF<0.1% in at least one ancestral group: 13/279 in Chinese (of which 4/13 were monomorphic). Two of the
13 SNPs that were monomorphic in Chinese people had MAF<0.1% in Africans.
32
B. Odds ratio (OR) for COPD per 1 standard deviation (SD) increase in weighted genetic risk score in each of six study groups (COPDGene [Non-Hispanic White],
COPDGene [African-American], ECLIPSE, GenKOLS, SPIROMICS, NETT-NAS). COPD was defined using GOLD 2-4 criteria. For means and standard deviations of the risk
scores in each group see Supplementary Table 21. The vertical black line indicates the null effect (an OR of 1). The point estimate of each study is represented by a
box proportional to the study’s weight, with the lines representing the lower and upper bounds of the 95% confidence interval. A fixed effect meta-analysis of the
five European-ancestry groups is denoted with a diamond, the width of which represents the 95% confidence interval for the estimate (I2 statistic=0).
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C. Odds ratios (OR) for COPD according to membership of deciles 2-10 of the weighted genetic risk score, with
decile 1 as the reference group (the 10% of individuals with the lowest genetic risk score). Each point
represents a meta-analysis of results for a given comparison (i.e. decile 2 vs reference, decile 3 vs reference …
decile 10 versus reference) in five external European-ancestry study groups (COPDGene, ECLIPSE, GenKOLS,
SPIROMICS, NETT-NAS). Deciles were calculated and models were run in each group separately. Points
represent odds ratios, and error bars correspond to 95% confidence intervals (Supplementary Table 22).
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Figure 4: Individual PheWAS with 279 variants (traits passing FDR 1% threshold)
Separate association of 279 variants with 2,411 traits (FDR<1%) in UK Biobank (n up to 379,337). In each category, the trait with the strongest association, i.e. highest –
log10(FDR), is shown first, followed by other traits in that category in descending order of –log10(FDR). Categories are colour-coded, and outcomes are denoted with a
circular or triangular point, according to whether they were coded as binary or quantitative. The top association per-category is labelled with its rsID number, and a plain
English label describing the trait. The letter at the beginning of each label allows easy cross-reference with the categories labelled in the legend. Zoomed in versions of each
category with visible trait names and directionality are available in Supplementary Figure 10. These plots have signed log10(FDR) values, where a positive values indicates
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that a positive SNP-trait association is concordant with the risk allele for reduced lung function (as measured by lower FEV1/FVC). Tabulated results of all SNP-trait PheWAS
associations associated at an FDR of<1% are available in Supplementary Table 23.
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Figure 5: PheWAS with genetic risk score (traits passing FDR 1% threshold)
Association of 279 variant weighted genetic risk score with 2,453 traits (FDR<1%) in UK Biobank (n up to 379,337). In each panel, the category with the strongest
association, i.e. highest –log10(FDR), is shown first, followed by all other associations in that category, ordered by descending order of –log10(FDR). Sample sizes varied
across traits and are available in Supplementary Table 25, along with the full summary statistics for each association, plus details of categorisation and plain English labels
for each trait. Trait categories are colour coded, and outcomes are denoted with a circular or triangular point, according to whether they were coded as binary or
quantitative. The sign of the log10(FDR) value is positive where an increase in the risk score (i.e. greater risk of COPD, reduced lung function) is associated with a positive
effect estimate for that trait. *QC refers to spirometry passing ERS/ATS criteria. HES=Hospital Episode Statistics.
A. Associations with respiratory traits.
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B. Associations with all other traits. ENT=Ear, Nose and Throat; FBC=Full Blood Count.
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Tables
Table 1: Genes implicated using gene expression data, protein level data and functional annotation
†Genes implicated by eQTL signals: Lung eQTL (n=1,111) and Blood eQTL (n=4,896) datasets and eleven GTEx (V7) tissues were screened: Artery Aorta (n=267), Artery
Coronary (n=152), Artery Tibial (n=388), Colon Sigmoid (n=203), Colon Transverse (n=246), Esophagus Gastroesophageal Junction (n=213), Esophagus Muscularis (n=335),
Lung (n=383), Small Intestine Terminal Ileum (n=122), Stomach (n=237), and Whole Blood (n=369); see Supplementary Table 13 for direction of gene expression for the
COPD risk (FEV1/FVC reducing) allele.
‡Genes implicated by pQTL signals: pQLT look up in 3,600 plasma proteins (n up to 3,300).
*Genes implicated because they contain a deleterious variant (Supplementary Table 11).
“Other traits” column lists the other lung function traits for which the sentinel was associated at P<5×10-9 in the meta-analysis of UK Biobank and SpiroMeta.
In total, 107 putative causal genes were identified: 8 by both a deleterious variant and an eQTL signal (including KIAA0753 implicated by two deleterious variants), 1 (NPNT)
by both an eQTL and a pQTL signal, 1 (SCARF2) by both a deleterious variant and a pQTL signal, 13 by a deleterious variant only, 81 by an eQTL signal only and 3 by a pQTL
signal only
Gene Phenotype Other traits
Novel Tier/
Previous Sentinel SNP Position (b37)
COPD
risk/alt Functionally implicated genes
DHDDS (intron) FVC FEV1 Tier 2 rs9438626 1:26,775,367 G/C DHDDS†
DHDDS (3’-UTR) FEV1 Tier 1 rs12096239 1:26,796,922 C/G HMGN2†, DHDDS†
NEXN (intron) FEV1/FVC FEV1 Tier 1 rs9661687 1:78,387,270 T/C NEXN†
DENND2D (intron) FEV1/FVC Tier 1 rs9970286 1:111,737,398 G/A CEPT1†, CHI3L2†, DRAM2†
C1orf54 (intron) PEF FVC Tier 1 rs11205354 1:150,249,101 C/A MRPS21†, RPRD2†, ECM1‡
KRTCAP2 FEV1/FVC Tier1 rs141942982 1: 155153537 T/C THBS4‡
RALGPS2 (intron) FEV1 Tier 1 rs4651005 1:178,719,306 C/T ANGPTL1†
LMOD1 (intron) FEV1/FVC FEV1 Tier 2 rs4309038 1:201,884,647 G/C SHISA4†
ATAD2B (intron) FVC FEV1 Tier 2 rs13009582 2:24,018,480 G/A UBXN2A†
PKDCC FVC Tier 1 rs4952564 2:42,243,850 A/G PKDCC†
ITGAV (intron) FEV1/FVC Tier 1 rs2084448 2:187,530,520 C/T ITGAV†
SPATS2L (intron) FEV1/FVC Tier 2 rs985256 2:201,208,692 C/A SPATS2L†
C2orf54 FVC FEV1 Tier 1 rs6437219 2:241,844,033 C/T C2orf54†*
MIR548G FVC Tier 1 rs1610265 3:99,420,192 T/C FILIP1L†
BCHE (exon) FEV1/FVC FEV1 Tier 1 rs1799807 3:165,548,529 C/T BCHE*
BTC (intron) FEV1/FVC FEV1/FVC Tier 1 rs62316310 4:75,676,529 G/A BTC*
LOC100996325 FEV1 FEV1/FVC, PEF Tier 1 rs11739847 5:609,661 A/G CEP72*
RNU6-71P FEV1 FVC, PEF Tier 1 rs2894837 6:56,336,406 G/A DST*
JAZF1 (intron) FEV1 Tier 1 rs1513272 7:28,200,097 C/T JAZF1†
MET (intron) FEV1/FVC Tier 2 rs193686 7:116,431,427 T/C MET†
IER5L FEV1 Tier 2 rs967497 9:131,943,843 G/A CRAT†, PPP2R4†, IER5L*
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Gene Phenotype Other traits
Novel Tier/
Previous Sentinel SNP Position (b37)
COPD
risk/alt Functionally implicated genes
DOCK9 FEV1/FVC Tier 1 rs11620380 13:99,665,512 A/C DOCK9*
CHAC1 FVC Tier 1 rs4924525 15:41,255,396 A/C INO80†, CHP1†, RAD51†
ATP2A3 FEV1/FVC Tier 1 rs8082036 17:3,882,613 G/C ATP2A3†
PITPNM3 FEV1 Tier 2 rs4796334 17:6,469,793 A/G KIAA0753†*, TXNDC17†, PITPNM3†
TNFSF12-TNFSF13 FEV1 Tier 2 rs4968200 17:7,448,457 C/G TNFSF13†, SENP3†
NCOR1 (intron) FVC FEV1 Tier 2 rs34351630 17:16,030,520 C/T ADORA2B†, TTC19†
ASPSCR1 (intron) FVC FEV1 Tier 1 rs59606152 17:79,952,944 C/T LRRC45*
C18orf8 FVC Tier 1 rs303752 18:21,074,255 A/G C18orf8†
ZFP82 FVC FVC, PEF Tier 2 rs2967516 19:36,881,643 A/G ZFP14†, ZFP82†
MFAP2 FEV1/FVC FEV1, PEF Previous rs9435733 1:17,308,254 C/T MFAP2†
LOC101929516 FEV1/FVC Previous rs755249 1:39,995,074 T/C PABPC4†
TGFB2 PEF FEV1/FVC Previous rs6604614 1:218,631,452 C/G TGFB2†
TRAF3IP1 FEV1 FVC, FEV1/FVC, PEF Previous rs6710301 2:239,441,308 C/A ASB1*
SLMAP (intron) FEV1 FEV1 Previous rs6445932 3:57,879,611 T/G SLMAP†
RSRC1 (intron) FVC FVC, FEV1/FVC Previous rs12634907 3:158,226,886 G/A RSRC1†
GSTCD (intron) FEV1 FEV1, FVC, PEF Previous rs11722225 4:106,766,430 T/C INTS12†
NPNT (intron) FEV1/FVC Previous rs34712979 4:106,819,053 A/G NPNT†‡
AP3B1 (intron) FVC Previous rs425102 5:77,396,400 G/T AP3B1†
SPATA9 FEV1/FVC Previous rs987068 5:95,025,146 C/G RHOBTB3†
P4HA2-AS1 FVC FEV1, PEF Previous rs3843503 5:131,466,629 A/T SLC22A5†, P4HA2†, C1QTNF5‡
CYFIP2 (intron) FEV1/FVC FEV1, PEF Previous rs11134766 5:156,908,317 T/C ADAM19†
ADAM19 (intron) FEV1/FVC Previous rs11134789 5:156,944,199 A/C ADAM19†*
DSP (intron) FEV1/FVC FEV1 Previous rs2076295 6:7,563,232 T/G DSP†
MIR588 FVC FVC, PEF Previous rs6918725 6:126,990,392 T/G CENPW†
GPR126 (exon) FEV1/FVC Previous rs17280293 6:142,688,969 A/G GPR126*
C1GALT1 (intron) FEV1/FVC FEV1 Previous rs4318980 7:7,256,490 A/G C1GALT1†
QSOX2 (3’-UTR) FVC Previous rs7024579 9:139,100,413 T/C QSOX2†
DNLZ (intron) FVC FEV1, FVC, PEF Previous rs4073153 9:139,259,349 G/A SNAPC4†, CARD9†, INPP5E†
CDC123 (intron) FEV1/FVC FEV1 Previous rs7090277 10:12,278,021 T/A NUDT5†
MYPN (intron) FVC FVC Previous rs10998018 10:69,962,954 A/G MYPN*
EML3 (intron) FEV1 FEV1 Previous rs71490394 11:62,370,155 G/A EEF1G†, ROM1†*, EML3†*
ARHGEF17 (intron) FEV1/FVC Previous rs2027761 11:73,036,179 C/T FAM168A†, ARHGEF17†*
RAB5B (intron) FEV1 PEF Previous rs1689510 12:56,396,768 C/G CDK2†
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Gene Phenotype Other traits
Novel Tier/
Previous Sentinel SNP Position (b37)
COPD
risk/alt Functionally implicated genes
LRP1 (intron) FEV1/FVC Previous rs11172113 12:57,527,283 T/C LRP1†
FGD6 (intron) FEV1/FVC Previous rs113745635 12:95,554,771 T/C FGD6†
RPAP1 FEV1/FVC Previous rs2012453 15:41,840,238 G/A ITPKA†, LTK†, TYRO3†, RPAP1†
AAGAB FVC FEV1, PEF Previous rs12917612 15:67,491,274 A/C AAGAB†, SMAD3†, IQCH†
THSD4 (intron) FEV1/FVC Previous rs1441358 15:71,612,514 G/T THSD4†
IL27 FEV1 Previous rs12446589 16:28,870,962 A/G
SBK1†, TUFM†, CCDC101†, SULT1A1†, SULT1A2†*, SH2B1†, NPIPL1†, CLN3†,
ATXN2L†, EIF3C†
MMP15 (intron) FEV1/FVC PEF Previous rs11648508 16:58,063,513 G/T MMP15†
SSH2 (intron) FEV1/FVC FEV1 Previous rs2244592 17:28,072,327 A/G EFCAB5†
FBXL20 (intron) FVC FVC, PEF Previous rs8069451 17:37,504,933 C/T CRKRS†, FBXL20†
MAPT-AS1 FEV1 Previous rs79412431 17:43,940,021 A/G LRRC37A4†, MAPT*
TSEN54 (intron) FEV1 PEF Previous rs9892893 17:73,525,670 G/T CASKIN2†, TSEN54*
LTBP4 (exon) FEV1/FVC Previous rs34093919 19:41,117,300 G/A LTBP4*
ABHD12 (intron) FEV1 FEV1, PEF Previous rs2236180 20:25,282,608 C/T PYGB†*
UQCC1 (5’-UTR) FVC FEV1 Previous rs143384 20:34,025,756 G/A UQCC1†, GDF5†
SLC2A4RG (intron) FVC FEV1/FVC Previous rs4809221 20:62,372,706 A/G LIME1†
SCARF2 (intron) FEV1 FEV1 Previous rs9610955 22:20,790,723 C/G SCARF2*‡
